The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): The Renal Impairment in Secondary care (RIISC) study; Rationale and protocol

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Stringer, Stephanie ^a,b   Sharma, Praveen ^b   Dutton, Mary ^a   Jesky, Mark ^a,b   Ng, Khai ^a,b   Kaur, Okdeep ^a   Chapple, Iain ^b,c   Dietrich, Thomas ^b   Ferro, Charles ^a,b   Cockwell, Paul ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Arterial stiffness; CKD progression; Inflammation; Observational cohort study; Periodontitis

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; HOMOCYSTEINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

AORTIC PULSE WAVE VELOCITY; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HUMAN; OBESITY; OBSERVATIONAL STUDY; PERIODONTICS; PROGNOSIS; PROSPECTIVE STUDY; PULSE WAVE; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS;

COHORT STUDIES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SECONDARY CARE;

EID: 84876966843     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-95     Document Type: Article

References (166)

1. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Eriksen BO, Ingebretsen OC, Kidney Int 2006 69 375 82 10.1038/sj.ki.5000058 16408129 (Pubitemid 43323090)
2. Kidney Disease and Cardiovascular Risk. Tonelli M, Pfeffer MA, Annu Rev Med 2007 58 123 39 10.1146/annurev.med.58.071105.111123 17081079 (Pubitemid 46706505)
3. Mortality Risk Stratification in Chronic Kidney Disease: One Size for All Ages? O'Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, Mehta K, J Am Soc Nephrol 2006 17 846 53 10.1681/ASN.2005090986 16452492
4. Chronic kidney disease management in the United Kingdom: {NEOERICA} project results. Stevens PE, O'Donoghue DJ, Lusignan S, Vlymen JV, Klebe B, Middleton R, Kidney Int 2007 72 92 9 10.1038/sj.ki.5002273 17440495 (Pubitemid 47014451)
5. Identifying Patients with Chronic Kidney Disease from General Practice Computer Records. De Lusignan S, Chan T, Stevens P, O'Donoghue D, Hague N, Dzregah B, Fam Pract 2005 22 234 41 10.1093/fampra/cmi026 15814579 (Pubitemid 40744499)
6. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, Chronic Kidney Disease Prognosis C, Lancet 2010 375 9731 2073 81 Epub 2010/05/21 20483451
7. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, Kidney Int 2011 80 1 93 104 Epub 2011/02/04 10.1038/ki.2010.531 21289597
8. Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, J Am Soc Nephrol 2004 15 1307 15 10.1097/01.ASN.0000123691.46138.E2 15100371 (Pubitemid 38526012)
9. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. Anavekar NS, McMurray JJV, Velazquez EJ, Solomon SD, Kober L, Rouleau J-L, N Eng J Med 2004 351 1285 95 10.1056/NEJMoa041365 (Pubitemid 39258422)
10. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y, N Eng J Med 2004 351 1296 305 10.1056/NEJMoa041031 (Pubitemid 39268908)
11. Survival and transplantation in end-stage renal disease: a prospective study of a multiethnic population. Jain P, Cockwell P, Little J, Ferring M, Nicholas J, Richards N, Nephrol Dial Transplant 2009 24 3840 6 10.1093/ndt/gfp455 19755474
12. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, Kidney Int 2011 79 12 1341 52 Epub 2011/02/11 10.1038/ki.2010.536 21307840
13. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Matsushita K, van der Velde M, Astor BC, Lancet 2010 375 2073 81 20483451
14. The Number, Quality, and Coverage of Randomized Controlled Trials in Nephrology. Strippoli GFM, Craig JC, Schena FP, J Am Soc Nephrol 2004 15 2 411 9 10.1097/01.ASN.0000100125.21491.46 14747388 (Pubitemid 38140782)
15. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Ann Intern Med 2012 156 8 570 81 Epub 2012/04/18 10.7326/0003-4819-156-8-201204170-00008 22508734
16. Randomised-controlled trials in chronic kidney disease-a call to arms! Ng KP, Townend JN, Ferro CJ, Int J Clin Pract 2012 66 10 913 5 Epub 2012/09/22 22994324
17. Arterial stiffness in chronic kidney disease: causes and consequences. Chue CD, Townend JN, Steeds RP, Ferro CJ, Heart 2010 96 11 817 23 Epub 2010/04/22 10.1136/hrt.2009.184879 20406771
18. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Menon V, Sarnak MJ, Am J Kidney Dis 2005 45 223 32 10.1053/j.ajkd.2004.09.022 15696466 (Pubitemid 40038066)
19. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet 1997 349 1857 63 9217756
20. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, N Eng J Med 2001 345 861 9 10.1056/NEJMoa011161
21. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, Lancet 2005 366 9502 2026 33 Epub 2005/12/13 10.1016/S0140-6736(05)67814-2 16338452 (Pubitemid 41773378)
22. Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease. Hemmelgarn BR, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, J Am Soc Nephrol 2007 18 3 993 9 10.1681/ASN. 2006080860 17267742 (Pubitemid 46434517)
23. Effects of multidisciplinary models of care for adult pre-dialysis patients with chronic kidney disease: a systematic review. Strand H, Parker D, Int J Evid Based Healthc 2012 10 1 53 9 Epub 2012/03/13 10.1111/j.1744-1609. 2012.00253.x 22405416
24. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Lancet 2011 377 9784 2181 92 10.1016/S0140-6736(11) 60739-3 21663949
25. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, N Eng J Med 2006 355 20 2071 84 10.1056/NEJMoa062276 (Pubitemid 44749316)
26. A randomized, controlled trial of early versus late initiation of dialysis. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, N Eng J Med 2010 363 7 609 19 Epub 2010/06/29 10.1056/NEJMoa1000552
27. Cohort studies: marching forward. Thadhani R, Tonelli M, Clin J Am Soc Nephrol 2006 1 5 1117 23 Epub 2007/08/19 10.2215/CJN.00080106 17699334
28. Randomized, controlled trials, observational studies, and the hierarchy of research designs. Concato J, Shah N, Horwitz RI, N Eng J Med 2000 342 25 1887 92 Epub 2000/06/22 10.1056/NEJM200006223422507 (Pubitemid 30419054)
29. Negative outcome studies in end-stage renal disease. Goldsmith D, Blood Purif 2008 26 1 63 6 Epub 2008/01/10 10.1159/000110567 18182799
30. Cardiovascular risk factors in predialysis patients: Baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Wheeler DC, Townend JN, Landray MJ, Kidney International. 2003 63 201 S3 10.1046/j.1523-1755.63.s84.45. x
31. Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, Journal of the American Society of Nephrology 2000 11 1 105 15 10616846 (Pubitemid 30020432)
32. Renal {Research} Institute {Symposium:} The Longitudinal Chronic Kidney Disease Study: A Prospective Cohort Study of Predialysis Renal Failure. Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, Seminars in Dialysis. 2003 16 418 23 10.1046/j.1525-139X.2003.16093.x 14629599 (Pubitemid 37550118)
33. Factors associated with vascular stiffness: cross-sectional analysis from the Chronic Renal Insufficiency Standards Implementation Study. Eddington H, Sinha S, Li E, Hegarty J, Ting J, Lane B, Nephron Clinical practice. 2009 112 3 190 8 Epub 2009/05/15 10.1159/000218108 19439990
34. Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline Characteristics and Associations with Kidney Function. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Clinical Journal of the American Society of Nephrology. 2009 4 1302 11 10.2215/CJN.00070109 19541818
35. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, J Am Soc Nephrol. 2003 14 7 Supp 2 148 53 Epub 2003/06/24 12819321
36. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Kidney Int. 2007 71 1 31 8 Epub 2006/11/09 10.1038/sj.ki.5002009 17091124 (Pubitemid 44967731)
37. Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW, Clin J Am Soc Nephrol 2011 6 2356 63 10.2215/CJN.02420311 21885790
38. Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, American journal of kidney diseases: the official journal of the National Kidney Foundation 2010 56 6 1082 94 10.1053/j.ajkd.2010.07.016
39. Hemodynamic correlates of proteinuria in chronic kidney disease. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Clin J Am Soc Nephrol. 2011 6 10 2403 10 Epub 2011/08/20 10.2215/CJN.01670211 21852669
40. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, American journal of hypertension. 2010 23 3 282 9 Epub 2009/12/19 10.1038/ajh.2009.240 20019670
41. Rapid Decline of Kidney Function Increases Cardiovascular Risk in the Elderly. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, J Am Soc Nephrol 2009 20 2625 30 10.1681/ASN.2009050546 19892934
42. Relationship between periodontal infections and systemic disease. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K, Clin Microbiol Infect 2007 13 Suppl 4 3 10 Epub 2007/11/06 17716290 (Pubitemid 47308185)
43. Molecular microbial diagnosis. Paster BJ, Dewhirst FE, Periodontol 2000 2009 51 38 44 Epub 2009/11/03 10.1111/j.1600-0757.2009.00316.x 19878468
44. Treatment of periodontitis and endothelial function. Tonetti MS, D'Aiuto F, Nibali L, Donald A, Storry C, Parkar M, N Eng J Med 2007 356 9 911 20 Epub 2007/03/03 10.1056/NEJMoa063186 (Pubitemid 46339910)
45. Periodontitis in systemic rheumatic diseases. de Pablo P, Chapple IL, Buckley CD, Dietrich T, Nat Rev Rheumatol 2009 5 4 218 24 Epub 2009/04/02 10.1038/nrrheum.2009.28 19337286
46. Oxidative and inflammatory status in Type 2 diabetes patients with periodontitis. Allen EM, Matthews JB, DJ OH, Griffiths HR, Chapple IL, J Clin Periodontol 2011 38 10 894 901 Epub 2011/09/03 10.1111/j.1600-051X.2011.01764.x 21883360
47. {CG73} Chronic kidney disease {NICE} guideline 2008
48. Use of a modified informed consent process among vulnerable patients: a descriptive study. Sudore RL, Landefeld CS, Williams BA, Barnes DE, Lindquist K, Schillinger D, J Gen Intern Med 2006 21 8 867 73 Epub 2006/08/03 10.1111/j.1525-1497.2006.00535.x 16881949 (Pubitemid 44024935)
49. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 5 373 83 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
50. Longitudinal Progression Trajectory of GFR Among Patients With CKD. Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, American journal of kidney diseases: the official journal of the National Kidney Foundation 2012 59 4 504 12 10.1053/j.ajkd.2011.12.009
51. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Chue CD, Edwards NC, Davis LJ, Steeds RP, Townend JN, Ferro CJ, Nephrol Dial Transplant 2011 26 2576 82 10.1093/ndt/gfq787 21248296
52. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 6 461 70 Epub 1999/03/13. 10.7326/0003-4819-130-6-199903160- 00002 10075613 (Pubitemid 29135798)
53. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, J Am Soc Nephrol 1993 4 5 1159 71 Epub 1993/11/01 8305642
54. A Community-Based Study of Explanatory Factors for the Excess Risk for Early Renal Function Decline in Blacks vs Whites With Diabetes: The Atherosclerosis Risk in Communities Study. Krop JS, Coresh J, Chambless LE, Shahar E, Watson RL, Szklo M, Arch Intern Med 1999 159 1777 83 10.1001/archinte.159.15.1777 10448782 (Pubitemid 29379142)
55. Progression of kidney dysfunction in the community-dwelling elderly. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, Kidney Int 2006 69 2155 61 10.1038/sj.ki.5000270 16531986 (Pubitemid 43882101)
56. Evaluation of measures of urinary albumin excretion in epidemiologic studies. Dyer AR, Greenland P, Elliott P, Daviglus ML, Claeys G, Kesteloot H, Am J Epidemiol 2004 160 11 1122 31 Epub 2004/11/25 10.1093/aje/kwh326 15561992 (Pubitemid 39557465)
57. Socioeconomic status and health: what we know and what we don't. Adler NE, Ostrove JM, Ann N Y Acad Sci 1999 896 3 15 Epub 2000/02/22 10.1111/j.1749-6632.1999.tb08101.x 10681884 (Pubitemid 30040234)
58. Equality of health: dream or reality? Acheson D, J R Coll Physicians Lond 1999 33 1 70 7 Epub 1999/04/07 10192075
59. Race, socioeconomic status, and the development of end-stage renal disease. Byrne C, Nedelman J, Luke RG, Am J Kidney Dis 1994 23 16 22 8285192 (Pubitemid 24021742)
60. Socioeconomic status and end-stage renal disease in the United States. Young EW, Mauger EA, Jiang KH, Port FK, Wolfe RA, Kidney Int 1994 45 3 907 11 Epub 1994/03/01 10.1038/ki.1994.120 8196296 (Pubitemid 24094507)
61. Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Perneger TV, Whelton PK, Klag MJ, Arch Intern Med 1995 155 11 1201 8 Epub 1995/06/12 10.1001/archinte.1995.00430110121013 7763126
62. End-stage renal disease in African-American and white men. 16-year MRFIT findings. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J, JAMA 1997 277 16 1293 8 Epub 1997/04/23 10.1001/jama.1997.03540400043029 9109467 (Pubitemid 27194353)
63. US minority groups and end-stage renal disease: a disproportionate share. Rostand SG, American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation. 1992 19 411 3
64. The excess incidence of diabetic end-stage renal disease among blacks. Brancati FL, Whittle JC, Whelton PK, Seidler AJ, Klag MJ, A population-based study of potential explanatory factors. JAMA. 1992 268 21 3079 84 Epub 1992/12/02
65. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Drey N, Roderick P, Mullee M, Rogerson M, Am J Kidney Dis 2003 42 4 677 84 Epub 2003/10/02 10.1016/S0272-6386(03)00916-8 14520617 (Pubitemid 37187367)
66. Relationship of socioeconomic status with cardiovascular risk factors and lifestyle in a Mediterranean population. Schroder H, Rohlfs I, Schmelz EM, Marrugat J, Eur J Nutr 2004 43 77 85 Epub 2004/04/15 10.1007/s00394-004-0443-9 15083314 (Pubitemid 38661220)
67. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Connolly VM, Kesson CM, Diabetes Care 1996 19 5 419 22 Epub 1996/05/01 10.2337/diacare.19.5.419 8732702 (Pubitemid 26143743)
68. Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. Winkleby MA, Jatulis DE, Frank E, Fortmann SP, Am J Public Health 1992 82 6 816 20 Epub 1992/06/01 10.2105/AJPH.82.6.816 1585961
69. Association of cardiovascular disease risk factors with socioeconomic position during childhood and during adulthood. Blane D, Hart CL, Smith GD, Gillis CR, Hole DJ, Hawthorne VM, BMJ 1996 313 7070 1434 8 Epub 1996/12/07 10.1136/bmj.313.7070.1434 8973230 (Pubitemid 26408030)
70. Department of the Environment TatR. DETR, Indices of Deprivation 2000 2000 [cited 2012 6th June 2012]; Available from: https://www.gov.uk/government/ publications/english-indices-of-deprivation-2010
71. Socioeconomic Status and Chronic Kidney Disease at Presentation to a Renal Service in the United Kingdom. Bello AK, Peters J, Rigby J, Rahman AA, El NM, Clin J Am Soc Nephrol 2008 3 1316 23 10.2215/CJN.00680208 18579673
72. A critical appraisal of the quality of quality-of-life measurements. Gill TM, Feinstein AR, JAMA 1994 272 8 619 26 Epub 1994/08/24. 10.1001/jama.1994. 03520080061045 7726894 (Pubitemid 24255222)
73. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Laupacis A, Muirhead N, Keown P, Wong C, Nephron 1992 60 3 302 6 Epub 1992/01/01 10.1159/000186769 1565182
74. Health-related quality of life and estimates of utility in chronic kidney disease. Gorodetskaya I, Zenios S, Mcculloch CE, Bostrom A, Hsu C-Y, Bindman AB, Kidney Int 2005 68 2801 8 10.1111/j.1523-1755.2005.00752.x 16316356 (Pubitemid 43251026)
75. EuroQol: the current state of play. Brooks R, Health Policy 1996 37 1 53 72 10.1016/0168-8510(96)00822-6 10158943 (Pubitemid 26191458)
76. A comparison of the EQ5D and SF6D across seven patient groups. Brazier J, Roberts J, Tsuchiya A, Busschbach J, Health Econ 2004 13 873 84 10.1002/hec.866 15362179 (Pubitemid 39264234)
77. A structured review of patient-reported outcome measures for people with chronic kidney disease. Gibbons E, Fitzpatrick R, Report to the Department of Health and NHS Kidney Care, 2010 2010 Epub 2010
78. Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. McKenzie L, van der Pol M, Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009 12 1 167 71 Epub 2008/07/19 10.1111/j.1524-4733.2008. 00405.x
79. Reference values for ambulatory blood pressure and self-measured blood pressure based on prospective outcome data. Verdecchia P, Blood Press Monit 2001 6 323 7 10.1097/00126097-200112000-00011 12055410 (Pubitemid 34194888)
80. Predicting Cardiovascular Risk Using Conventional Vs Ambulatory Blood Pressure in Older Patients With Systolic Hypertension. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, De Leeuw PW, JAMA 1999 282 539 46 10.1001/jama.282.6.539 10450715 (Pubitemid 29380290)
81. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. Beckett L, Godwin M, BMC Cardiovasc Disord 2005 5 18 10.1186/1471-2261-5-18 15985180 (Pubitemid 41460660)
82. Clinical decision-making in hypertension using an automated {(BpTRU{\textbar}[trade]{\textbar})} measurement device. Graves JW, Nash C, Burger K, Bailey K, Sheps SG, J Hum Hypertens 2003 17 823 7 10.1038/sj.jhh. 1001626 14704726 (Pubitemid 38028639)
83. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, BMJ 2011 342 286 10.1136/bmj.d286 21300709
84. Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of bptru in kidney disease. Brothwell SDM, Ferro C, Stringer S, Cockwell P, Am Soc Nephrol 2011 Philadelphia: J Am Soc Nephrol
85. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Stroke; a journal of cerebral circulation 2001 32 2 454 60 Epub 2001/02/07 10.1161/01.STR.32.2.454 23700198 (Pubitemid 32155234)
86. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Cecelja M, Chowienczyk P, Hypertension 2009 54 6 1328 36 Epub 2009/11/04 10.1161/HYPERTENSIONAHA.109.137653 19884567
87. Basal NO locally modulates human iliac artery function in vivo. Schmitt M, Avolio A, Qasem A, McEniery CM, Butlin M, Wilkinson IB, Hypertension 2005 46 1 227 31 Epub 2005/05/04 10.1161/01.HYP.0000164581.39811.bd 15867142 (Pubitemid 40946519)
88. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. Avolio AP, Van Bortel LM, Boutouyrie P, Cockcroft JR, McEniery CM, Protogerou AD, Hypertension 2009 54 2 375 83 Epub 2009/07/01 10.1161/HYPERTENSIONAHA.109.134379 19564542
89. What is the role of the aorta in directing coronary blood flow? Davies JE, Parker KH, Francis DP, Hughes AD, Mayet J, Heart 2008 94 12 1545 7 Epub 2008/07/18 10.1136/hrt.2008.144808 18632832
90. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. O'Rourke MF, Safar ME, Hypertension 2005 46 1 200 4 Epub 2005/05/25 10.1161/01.HYP.0000168052.00426.65 15911742 (Pubitemid 40946514)
91. Aortic and large artery compliance in end-stage renal failure. London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Kidney Int 1990 37 1 137 42 Epub 1990/01/01 10.1038/ki.1990.19 2299800 (Pubitemid 20023778)
92. Systolic flow augmentation in hearts ejecting into a model of stiff aging vasculature. Influence on myocardial perfusion-demand balance. Saeki A, Recchica F, Kass DA, Circ Res 1995 76 1 132 41 Epub 1995/01/01 10.1161/01.RES.76.1.132 8001271
93. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Eur Heart J 2006 27 2588 605 10.1093/eurheartj/ehl254 17000623 (Pubitemid 44627304)
94. Markers of Arterial Stiffness Are Risk Factors for Progression to End-Stage Renal Disease among Patients with Chronic Kidney Disease Stages 4 and 5. Taal MW, Sigrist MK, Fakis A, Fluck RJ, McIntyre CW, Nephron Clin Pract 2007 107 177 c81 10.1159/000110678 17975325
95. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Takenaka T, Mimura T, Kanno Y, Suzuki H, Am J Nephrol 2005 25 5 417 24 Epub 2005/08/20 10.1159/000087605 16110203 (Pubitemid 41433884)
96. Time for reflection predicts the progression of renal dysfunction in patients with nondiabetic chronic kidney disease. Takenaka T, Mimura T, Kikuta T, Kato N, Inoue T, Kanno Y, Clinical and experimental hypertension (New York, NY: 1993) 2009 31 3 220 30 Epub 2009/04/24 10.1080/10641960902822476
97. Aortic Stiffness Is Independently Associated With Rate of Renal Function Decline in Chronic Kidney Disease Stages 3 and 4. Ford ML, Tomlinson LA, Chapman TPE, Rajkumar C, Holt SG, Hypertension 2010 55 1110 5 10.1161/HYPERTENSIONAHA. 109.143024 20212269
98. Arterial Stiffness in Mild-to-Moderate {CKD}. Upadhyay A, Hwang S-J, Mitchell GF, Vasan RS, Vita JA, Stantchev PI, J Am Soc Nephrol 2009 20 2044 53 10.1681/ASN.2009010074 19608701
99. Reproducibility of derived central arterial waveforms in patients with chronic renal failure. 2002
100. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. DeLoach SS, Townsend RR, Clin J Am Soc Nephrol 2008 3 1 184 92 Epub 2008/01/08. 10.2215/CJN.03340807 18178784
101. Validating a new oscillometric device for aortic pulse wave velocity measurements in children and adolescents. Kracht D, Shroff R, Baig S, Doyon A, Jacobi C, Zeller R, American Journal of Hypertension 2011 24 12 1294 9 Epub 2011/08/26 10.1038/ajh.2011.147 21866186
102. Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM, Hypertension Research. 2009 32 1079 85 10.1038/hr.2009.154 19779487
103. Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices. Kis E, Cseprekal O, Kerti A, Salvi P, Benetos A, Tisler A, Hypertension research: official journal of the Japanese Society of Hypertension 2011 34 11 1197 202 Epub 2011/07/29 10.1038/hr.2011.103
104. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Nephrology Dialysis Transplantation. 2011 26 214 20 10.1093/ndt/gfq369
105. Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients. Meerwaldt R, Hartog JWL, Graaff R, Huisman RJ, Links TP, den Hollander NC, Journal of the American Society of Nephrology. 2005 16 3687 93 10.1681/ASN.2005020144 16280473 (Pubitemid 46211290)
106. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Hartog JWL, de Vries APJ, Bakker SJL, Graaff R, van Son WJ, van der Heide JJH, Nephrology Dialysis Transplantation 2006 21 8 2263 9 10.1093/ndt/gfl132 (Pubitemid 44295054)
107. AGE reader cardiovascular assessement device instructions for use. Diagnoptics
108. Simple non-invasive assessment of advanced glycation endproduct accumulation. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Diabetologia 2004 47 7 1324 30 Epub 2004/07/10 15243705 (Pubitemid 39093330)
109. Plasma Levels of Pentosidine in Diabetic Patients: An Advanced Glycation End Product. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Journal of the American Society of Nephrology. 1998 9 1681 8 9727377
110. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Hricik DE, Wu YC, Schulak A, Friedlander MA, Clin Transplant 1996 10 6 Pt 1 568 73 Epub 1996/12/01 8996781 (Pubitemid 27010902)
111. Advanced glycation end products and mortality in hemodialysis patients. Schwedler SB, Metzger T, Schinzel R, Wanner C, Kidney Int 2002 62 1 301 10 Epub 2002/06/26 10.1046/j.1523-1755.2002.00423.x 12081592 (Pubitemid 34754076)
112. Boerma JT, Colin Mathers DMF, World Health Organization, The Global Burden of Disease: 2004 update WHO 2004 146
113. Association between obesity and kidney disease: a systematic review and meta-analysis. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ, Kidney Int 2008 73 1 19 33 Epub 2007/10/12 10.1038/sj.ki.5002586 17928825 (Pubitemid 350273639)
114. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH, BMC Public Health. 2009 9 88 Epub 2009/03/27 10.1186/1471-2458-9-88 19320986
115. Socioeconomic status and reduced kidney function in the Whitehall II Study: role of obesity and metabolic syndrome. Al-Qaoud TM, Nitsch D, Wells J, Witte DR, Brunner EJ, Am J Kidney Dis 2011 58 3 389 97 Epub 2011/07/02 10.1053/j.ajkd.2011.04.017 21719176
116. Bariatric surgery and progression of chronic kidney disease. Navaneethan SD, Yehnert H, Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery 2009 5 6 662 5 Epub 2009/04/11 10.1016/j.soard.2009.01.006
117. Thigh circumference and risk of heart disease and premature death: prospective cohort study. Heitmann BL, Frederiksen P, BMJ. 2009 339 3292 10.1136/bmj.b3292 19729416
118. Atherosclerosis-an inflammatory disease. Ross R, The New England journal of medicine. 1999 340 115 26 10.1056/NEJM199901143400207 9887164 (Pubitemid 29054847)
119. Periodontal disease and cardiovascular disease. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S, Journal of periodontology 1996 67 10 Suppl 1123 37 Epub 1996/10/01 8910831 (Pubitemid 126613093)
120. Periodontal diseases. Pihlstrom BL, Michalowicz BS, Johnson NW, The Lancet. 2005 366 1809 20 10.1016/S0140-6736(05)67728-8 (Pubitemid 41642647)
121. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kshirsagar AV, Craig RG, Moss KL, Beck JD, Offenbacher S, Kotanko P, Kidney International. 2009 75 746 51 10.1038/ki.2008.660 19165177
122. Case definitions for use in population-based surveillance of periodontitis. Page RC, Eke PI, Journal of periodontology 2007 78 7 Suppl 1387 99 Epub 2007/08/19 17608611
123. Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Annals of Internal Medicine. 2007 147 19 27 10.7326/0003-4819-147-1-200707030-00004 17606957 (Pubitemid 351664630)
124. Serum Creatinine, Cystatin C, and β-Trace Protein in Diagnostic Staging and Predicting Progression of Primary Nondiabetic Chronic Kidney Disease. Spanaus K-S, Kollerits B, Ritz E, Hersberger M, Kronenberg F, von Eckardstein A, Clinical Chemistry 2010 56 740 9 10.1373/clinchem.2009.138826 20224047
125. Biomarkers in chronic kidney disease: a review. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE, Kidney International. 2011 80 806 21 10.1038/ki.2011.198 21697815
126. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Clinical Journal of the American Society of Nephrology. 2009 4 337 44 10.2215/CJN.03530708 19176795
127. Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Early Diabetic Nephropathy in Type 1 Diabetes. Tarnow L, Hovind P, Teerlink T, Stehouwer CDA, Parving H-H, Diabetes care. 2004 27 765 9 10.2337/diacare.27.3.765 14988299 (Pubitemid 38280547)
128. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Nephrology Dialysis Transplantation. 2009 24 1884 8 10.1093/ndt/gfn716
129. Asymmetric Dimethylarginine and Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Journal of the American Society of Nephrology. 2005 16 2456 61 10.1681/ASN.2005020179 15930091 (Pubitemid 41725064)
130. Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C, Journal of the American Society of Nephrology. 2005 16 2449 55 10.1681/ASN.2005010076 15944335 (Pubitemid 41725063)
131. Natriuretic Peptides in Chronic Kidney Disease. Tagore R, Ling LH, Yang H, Daw H-Y, Chan Y-H, Sethi SK, Clinical Journal of the American Society of Nephrology. 2008 3 1644 51 10.2215/CJN.00850208 18632852
132. B-Type Natriuretic Peptide Concentrations Predict the Progression of Nondiabetic Chronic Kidney Disease: The Mild-to-Moderate Kidney Disease Study. Spanaus K-S, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, Clinical Chemistry. 2007 53 1264 72 10.1373/clinchem.2006.083170 17478561 (Pubitemid 47020982)
133. Relationship Between Homocysteine and Mortality in Chronic Kidney Disease. Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Circulation. 2006 113 1572 7 10.1161/CIRCULATIONAHA.105.570127 16549639 (Pubitemid 43739416)
134. Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria: The Hoorn Study. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Arteriosclerosis, thrombosis, and vascular biology. 2001 21 74 81 10.1161/01.ATV.21.1.74 11145936 (Pubitemid 32061930)
135. Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Sarnak MJ, Poindexter A, Wang S-R, Beck GJ, Kusek JW, Marcovina SM, Kidney International. 2002 62 2208 15 10.1046/j.1523-1755.2002.00677.x 12427147 (Pubitemid 35366177)
136. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving H-H, Kidney International. 2008 74 649 54 10.1038/ki.2008.201 18496510
137. Serum Adiponectin and Progression of Diabetic Nephropathy in Patients With Type 1 Diabetes. Saraheimo M, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Heikkilä O, Diabetes care. 2008 31 1165 9 10.2337/dc07-2306 18346990
138. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, Barnett AH, Expert Opinion on Therapeutic Targets. 2008 12 667 76 10.1517/14728222.12.6.667 18479214 (Pubitemid 351877296)
139. Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Journal of the American Society of Nephrology. 2007 18 2600 8 10.1681/ASN.2006080936 17656479 (Pubitemid 47378877)
140. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Prodjosudjadi W, Gerritsma JS, van Es LA, Daha MR, Bruijn JA, Clinical nephrology 1995 44 3 148 55 Epub 1995/09/01 8556830
141. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, J Am Soc Nephrol 1996 7 6 906 13 Epub 1996/06/01 8793800 (Pubitemid 27465985)
142. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Eardley KS, Zehnder D, Quinkler M, Lepenies J, Bates RL, Savage CO, Kidney Int 2006 69 7 1189 97 Epub 2006/04/13 10.1038/sj.ki.5000212 16609683
143. Multiple loci associated with indices of renal function and chronic kidney disease. Köttgen A, Glazer NL, Dehghan A, Hwang S-J, Katz R, Li M, Nature genetics. 2009 41 712 7 10.1038/ng.377 19430482
144. Genetic polymorphisms and the risk of progressive renal failure in elderly Hungarian patients. Zsom M, Fulop T, Zsom L, Barath A, Maroti Z, Endreffy E, Hemodialysis international International Symposium on Home Hemodialysis 2011 15 4 501 8 Epub 2011/11/25 10.1111/j.1542-4758.2011.00593.x 22111818
145. Genetic loci influencing kidney function and chronic kidney disease. Chambers JC, Zhang W, Lord GM, van der Harst P, Lawlor DA, Sehmi JS, Nature genetics 2010 42 5 373 5 Epub 2010/04/13 10.1038/ng.566 20383145
146. Genome-wide association and functional follow-up reveals new loci for kidney function. Pattaro C, Kottgen A, Teumer A, Garnaas M, Boger CA, Fuchsberger C, PLoS genetics 2012 8 3 1002584 Epub 2012/04/06 10.1371/journal.pgen.1002584 22479191
147. A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, JAMA: The Journal of the American Medical Association. 2011 305 1553 9 10.1001/jama.2011.451
148. Renal risk scores: Progress and prospects. Taal MW, Brenner BM, Kidney International. 2008 73 1216 9 10.1038/ki.2008.36 18322541 (Pubitemid 351693152)
149. The Use of Targeted Biomarkers for Chronic Kidney Disease. Devarajan P, Advances in chronic kidney disease. 2010 17 469 79 10.1053/j.ackd.2010.09.002 21044769
150. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Harrell FE Jr, Lee KL, Mark DB, Statistics in medicine 1996 15 4 361 87 Epub 1996/02/28 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 8668867 (Pubitemid 26072233)
151. Relation Between Kidney Function, Proteinuria, and Adverse Outcomes. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, JAMA: The Journal of the American Medical Association. 2010 303 423 9 10.1001/jama.2010.39
152. Blood pressure and end-stage renal disease in men. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, The New England journal of medicine 1996 334 1 13 8 Epub 1996/01/04 10.1056/NEJM199601043340103 7494564 (Pubitemid 26012498)
153. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Goteborg. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Sweden. Journal of hypertension. 1985 3 2 167 76 Epub 1985/04/01 10.1097/00004872-198504000-00010 (Pubitemid 15117571)
154. Blood pressure and renal function: therapeutic implications. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL, Journal of hypertension 1996 14 11 1259 63 Epub 1996/11/01 10.1097/00004872-199611000- 00001 8934351 (Pubitemid 26377207)
155. Network SIG, Scottish Intercollegiate Guidelines Network Diagnosis and Management of Chronic Kidney Disease 2008 [14/05/2012]; Available from: http://www.sign.ac.uk/pdf/sign103.pdf
156. KDIGO, KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
157. Risk profile in chronic kidney disease stage 3: older versus younger patients. McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW, Nephron Clinical practice 2011 119 4 269 76 Epub 2011/09/17 10.1159/000329109 21921639
158. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Black PS C, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C, 1Section of Population Health UoA, Aberdeen, UK, 2Health Economics Research Unit UoA, Aberdeen, UK, 3NHS Grampian A, UK, 4Grampian University Hospitals NHS Trust A, UK, Health technology assessment (Winchester, England). 2010 14 21 1 184
159. GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Brändström E, Grzegorczyk A, Jacobsson L, Friberg P, Lindahl A, Aurell M, Nephrology Dialysis Transplantation 1998 13 1176 82 10.1093/ndt/13.5.1176 (Pubitemid 28227194)
160. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. Feldman HI, Journal of the American Society of Nephrology. 2003 14 148S 53 10.1097/01.ASN.0000070149.78399.CE
161. Bone disease in CKD. Ott SM, Curr Opin Nephrol Hypertens 2012 Epub 2012/04/26
162. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Isakova T, Curr Opin Nephrol Hypertens 2012 21 3 334 40 Epub 2012/04/11 10.1097/MNH.0b013e328351a391 22487610
163. Hays RD KJ, Mapes DL, Coons SJ, Amin N, Carter WD, Camberg C, Kidney Disease Quality of Life Short Form (KDQOL-SF™), Version 1.3 1997 23613285
164. Ware JE, SF-36® Health Survey Update. SF-36.org 1996 [cited 2012 15th May]; Available from: http://www.sf-36.org/tools/SF36.shtml 23699910
165. Renal quality outcomes framework and eGFR: impact on secondary care. Phillips LA, Donovan KL, Phillips AO, QJM: monthly journal of the Association of Physicians 2009 102 6 415 23 Epub 2009/04/08 10.1093/qjmed/hcp030 19349287
166. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Muntner P, He J, Astor BC, Folsom AR, Coresh J, Journal of the American Society of Nephrology: {JASN} 2005 16 529 38 10.1681/ASN.2004080656 15625072 (Pubitemid 41725151)